07.26.17
$12.5 Billion
KEY EXECUTIVES:
Vincent A. Forlenza, Chairman, President, and CEO
Gary M. Cohen, Exec. VP and President, Global Health
Alexandre Conroy, Exec. VP and President, Europe, EMA, and the Americas
James Lim, Exec. VP and President, Greater Asia
Alberto Mas, Exec. VP and President—Life Sciences Segment
Thomas E. Polen, Exec. VP and President—Medical Segment
Christopher R. Reidy, Exec. VP, CFO, and Chief Administrative Officer
Nabil Shabshab, Exec. VP, Strategic Planning and Chief Marketing Officer
Jeffrey S. Sherman, Exec. VP and General Counsel
Stephen Sichak, Exec. VP, Integrated Supply Chain
Ellen R. Strahlman, M.D., Exec. VP—R&D, and Chief Medical Officer
Linda M. Tharby, Exec. VP and Chief Human Resource Officer
NUMBER OF EMPLOYEES: 50,928
GLOBAL HEADQUARTERS: Franklin Lakes, N.J.
Back in October 2014, BD made headlines when the company announced it was acquiring fellow MPO Top 30 perennial list member CareFusion for a purchase price of $12.2 billion. While the dust still hasn’t entirely settled on that transaction (although it did formally close in March 2015), BD made an even bigger splash in medtech M&A news in more recent months with the announcement that it would be gobbling up yet another member of MPO’s annual list. In April 2017, it was revealed that C.R. Bard would become the next acquisition for the medtech giant. At a purchase price of $24 billion, the transaction comes in just behind Abbott’s $25 billion price tag for St. Jude Medical Inc.—a deal that closed just days after the ball dropped to mark the start of 2017.
By comparison, BD’s 2016 fiscal year (which doesn’t follow the standard calendar, but instead runs from October through the following September) was relatively quiet in terms of acquisitions. Actually, BD ended up on the selling side a few times during the 12-month period.
Most notable, BD sold a controlling 50.1 percent of its Respiratory Solutions business to funds advised by Apax Partners. With the remaining 49.9 percent of the business, BD partnered with the global private equity firm in the formation of a new, stand-alone company of which Apax Funds is the majority owner. Vyaire Medical, the name of the new entity, was officially launched in October 2016 following the formal close of the transaction between BD and Apax.
“We have been proactively targeting the industry for respiratory devices and have been impressed with the continued progress the company has made over the past few years,” Steven Dyson, partner at Apax Partners, said in a release that first announced the sale. “We are pleased to have the opportunity to work with the entire team in further developing Respiratory Solutions’ position as a focused and leading global player. In order to take advantage of this opportunity, we are highly supportive of an investment program to further strengthen the business’s existing platform, both organically and through acquisitions.”
Vyaire Medical is made up of all the former BD Respiratory Solutions businesses, which included Ventilation, Respiratory Diagnostics, Vital Signs, and AirLife. At the time of the sale’s announcement, the combined estimated annual revenue of the individual pieces was $900 million.
“We are delighted to launch this new brand, Vyaire Medical, built on the foundation of excellent products, talented people, and the industry standard for service and support for our customers,” Dave Mowry, CEO of Vyaire Medical, said in a release announcing the launch of the new entity. “Our new company will be focused on providing improved patient outcomes and increased value to our customers through a collaborative partnership that brings innovation to these market segments.”
Analyst Insights: The core question for BD will be how to handle the CR Bard product portfolio. Bard struggled to gain meaningful global position with several of its smaller product lines and never matched the OUS position of its rivals. BD will need exceptional discipline to select which lines to keep and which to sell as well as building Bard into an international competitor of note.
Further, BD performed two additional noteworthy divestitures during the 2016 fiscal year. In January, the company announced that it was selling its Rx business, including a pharmaceutical manufacturing plant in Wilson, N.C., along with the BD Simplist line of seven drugs that are provided in ready-to-administer, prefilled glass syringes, to Fresenius Kabi USA. In the same breath, the companies also declared that they signed a 10-year supply and distribution agreement under which Fresenius would supply BD with a portfolio of intravenous solutions. The other transaction alluded to previously was the sale of BD’s vertebral augmentation solutions business to Stryker. That transaction included the AVAmax, AVAtex, and AVAprep brand. The financial details and terms of the sales for both transactions were not disclosed.
BD did, however, have very positive financial news to disclose in terms of its 2016 fiscal year. The company moved up several spots on MPO’s Top Company list from the previous year, just as it had last year (No. 8 in 2016; No. 12 in 2015). With the official close of the CareFusion acquisition completed, the additional product offerings and revenue streams had a substantial impact on BD’s performance. The company’s revenues of $12.5 billion in 2016 reflected a 21.4 percent increase over 2015’s $10.3 billion (which had been a 21.7 percent increase over 2014’s $8.4 billion in revenues). Further, this performance was achieved in spite of the termination of a distribution agreement that was tied to the divested Respiratory Solutions unit and an unfavorable foreign currency translation impact of approximately 3.1 percent.
More specifically, looking at the volume growth that originated from specific units of BD, there were a number of areas that accounted for the overall gains the company saw in 2016.
The Medical segment experienced volume growth due to the Medication and Procedural Solutions unit’s sales of safety-engineered products, the Diabetes Care business’s sales of pen needles, and the Pharmaceutical Systems unit’s sales of self-injection systems. Life Sciences noted growth as a result of global sales of safety-engineered products from Preanalytical Systems, automated platform sales from Diagnostic Systems, and research instrument and reagent sales by the Biosciences unit. Infusion disposables and self-injection systems drove growth for the U.S. Medical segment. Internationally, safety-engineered and flush products drove growth for the Medical segment, while Life Sciences saw it from safety-engineered products, microbiology, women’s health platforms, and cancer platforms.
Examining the numbers for each segment of BD—Medical and Life Sciences—provides greater insight on where the company’s market strengths truly exist. The Medical segment, which accounted for $8.65 billion of the 2016 overall revenues, saw a 34 percent increase over 2015, a result of having the integrated CareFusion offerings as part of the company’s revenue streams for the full year (versus only half of the year in the 2015 fiscal year). Broken down further, by specific unit within the segment, the Medication and Procedural Solutions unit is the largest contributor to the company’s revenue, reporting $3.4 billion. The other units in the segment contributed revenue totals as follows: Medication Management Solutions—$2.2 billion; Diabetes Care—$1 billion; Pharmaceutical Systems—1.2 billion; and Respiratory Solutions—$824 million.
The Life Sciences segment contributed $3.8 billion to BD’s total revenues, a figure that was flat versus the prior year (up 0.2 percent). That segment is broken down into three, almost equal (in terms of revenue) units. Preanalytical Systems leads the segment with $1.4 billion, followed by Diagnostic Systems at $1.3 billion, and Biosciences posting $1.1 billion.
ANALYST INSIGHTS: Known for its solutions in cancer and diabetes, most were surprised when BD announced in May that it was acquiring CR Bard for $24 Billion. This acquisition will help BD leverage its global presence by accelerating end-to- end medication management and infection prevention, while creating new growth opportunities across a range of clinically impactful segments. It will also provide additional strength to BDs portfolio in the surgical arena. The key to success of this mega merger will very much be dependent on its execution of the post-merger integration.
In terms of region, the company’s U.S. sales led revenue, representing $6.9 billion, compared to international sales that accounted for $5.6 billion. This was a reversal of 2015’s figures, which had international at $5.2 billion versus U.S. revenue of $5.1 billion. Again, the inclusion of CareFusion’s product lines had a direct impact on the increase in U.S. sales totals.
Enjoying increased sales revenues year over year from 2014 through 2016, the company mirrored those increases in its research and development spending. While a majority of the company’s R&D activity takes place within the United States, BD does conduct some internationally in China, France, India, Ireland, and Singapore. It also collaborates with universities and medical centers to further investigate potential new innovations. In total, BD spent $828 million on R&D in 2016. This represented a marked increase over 2015, during which $632 million was spent, and 2014, which saw R&D expenditures of $550 million.
Earlier investments in R&D are finally bearing fruit for the company as the 2016 fiscal year saw a fair number of notable product launches, FDA clearances/approvals, and CE mark notifications.
The Veritor system wasn’t the only example of BD’s interest in connected technologies in 2016. The company also announced a collaboration agreement with Edwards Lifesciences in which the two firms would enable interoperability between patient hemodynamic management and IV fluid administration. Specifically, the agreement leverages Edwards’ advanced hemodynamic monitoring systems and fluid management algorithms and BD’s (CareFusion) Alaris Infusion Systems.
“This collaboration builds on our history of innovation in patient monitoring infusion solutions and the investments we’ve made in our interoperability platform that integrates the Alaris Infusion System to HIT systems. We are excited to extend that interoperability capability to integration with patient monitoring. Our vision is to create interoperability with many different types of systems and devices to help improve the patient care, efficiency, and cost of IV therapy,” J.C. Kyrillos, worldwide vice president and general manager of Infusion Solutions for BD, said in a statement announcing the agreement.
Further addressing medtech connectivity, BD announced another “partnership” of sorts in which the company stated that it was using AT&T Internet of Things (IoT) services to connect its wireless health devices. At the 2016 Healthcare Information and Management Systems Society annual meeting, the company presented the aforementioned Veritor System, which leverages the AT&T technology. BD is continuing to work with the communications giant on wireless connectivity solutions for other products.
“This collaboration with AT&T further strengthens BD’s continued progress in health IT and is a significant step forward for the company in becoming a leader in medical IoT technology,” said David Feygin, vice president, Health IT and Strategic Innovation at BD. “We are continuing to evaluate how the addition of information technology to our current capabilities could further benefit our customers and patients.”
KEY EXECUTIVES:
Vincent A. Forlenza, Chairman, President, and CEO
Gary M. Cohen, Exec. VP and President, Global Health
Alexandre Conroy, Exec. VP and President, Europe, EMA, and the Americas
James Lim, Exec. VP and President, Greater Asia
Alberto Mas, Exec. VP and President—Life Sciences Segment
Thomas E. Polen, Exec. VP and President—Medical Segment
Christopher R. Reidy, Exec. VP, CFO, and Chief Administrative Officer
Nabil Shabshab, Exec. VP, Strategic Planning and Chief Marketing Officer
Jeffrey S. Sherman, Exec. VP and General Counsel
Stephen Sichak, Exec. VP, Integrated Supply Chain
Ellen R. Strahlman, M.D., Exec. VP—R&D, and Chief Medical Officer
Linda M. Tharby, Exec. VP and Chief Human Resource Officer
NUMBER OF EMPLOYEES: 50,928
GLOBAL HEADQUARTERS: Franklin Lakes, N.J.
Back in October 2014, BD made headlines when the company announced it was acquiring fellow MPO Top 30 perennial list member CareFusion for a purchase price of $12.2 billion. While the dust still hasn’t entirely settled on that transaction (although it did formally close in March 2015), BD made an even bigger splash in medtech M&A news in more recent months with the announcement that it would be gobbling up yet another member of MPO’s annual list. In April 2017, it was revealed that C.R. Bard would become the next acquisition for the medtech giant. At a purchase price of $24 billion, the transaction comes in just behind Abbott’s $25 billion price tag for St. Jude Medical Inc.—a deal that closed just days after the ball dropped to mark the start of 2017.
By comparison, BD’s 2016 fiscal year (which doesn’t follow the standard calendar, but instead runs from October through the following September) was relatively quiet in terms of acquisitions. Actually, BD ended up on the selling side a few times during the 12-month period.
Most notable, BD sold a controlling 50.1 percent of its Respiratory Solutions business to funds advised by Apax Partners. With the remaining 49.9 percent of the business, BD partnered with the global private equity firm in the formation of a new, stand-alone company of which Apax Funds is the majority owner. Vyaire Medical, the name of the new entity, was officially launched in October 2016 following the formal close of the transaction between BD and Apax.
“We have been proactively targeting the industry for respiratory devices and have been impressed with the continued progress the company has made over the past few years,” Steven Dyson, partner at Apax Partners, said in a release that first announced the sale. “We are pleased to have the opportunity to work with the entire team in further developing Respiratory Solutions’ position as a focused and leading global player. In order to take advantage of this opportunity, we are highly supportive of an investment program to further strengthen the business’s existing platform, both organically and through acquisitions.”
Vyaire Medical is made up of all the former BD Respiratory Solutions businesses, which included Ventilation, Respiratory Diagnostics, Vital Signs, and AirLife. At the time of the sale’s announcement, the combined estimated annual revenue of the individual pieces was $900 million.
“We are delighted to launch this new brand, Vyaire Medical, built on the foundation of excellent products, talented people, and the industry standard for service and support for our customers,” Dave Mowry, CEO of Vyaire Medical, said in a release announcing the launch of the new entity. “Our new company will be focused on providing improved patient outcomes and increased value to our customers through a collaborative partnership that brings innovation to these market segments.”
Analyst Insights: The core question for BD will be how to handle the CR Bard product portfolio. Bard struggled to gain meaningful global position with several of its smaller product lines and never matched the OUS position of its rivals. BD will need exceptional discipline to select which lines to keep and which to sell as well as building Bard into an international competitor of note.
—Tony Freeman, President, AS Freeman Advisors LLC
Further, BD performed two additional noteworthy divestitures during the 2016 fiscal year. In January, the company announced that it was selling its Rx business, including a pharmaceutical manufacturing plant in Wilson, N.C., along with the BD Simplist line of seven drugs that are provided in ready-to-administer, prefilled glass syringes, to Fresenius Kabi USA. In the same breath, the companies also declared that they signed a 10-year supply and distribution agreement under which Fresenius would supply BD with a portfolio of intravenous solutions. The other transaction alluded to previously was the sale of BD’s vertebral augmentation solutions business to Stryker. That transaction included the AVAmax, AVAtex, and AVAprep brand. The financial details and terms of the sales for both transactions were not disclosed.
BD did, however, have very positive financial news to disclose in terms of its 2016 fiscal year. The company moved up several spots on MPO’s Top Company list from the previous year, just as it had last year (No. 8 in 2016; No. 12 in 2015). With the official close of the CareFusion acquisition completed, the additional product offerings and revenue streams had a substantial impact on BD’s performance. The company’s revenues of $12.5 billion in 2016 reflected a 21.4 percent increase over 2015’s $10.3 billion (which had been a 21.7 percent increase over 2014’s $8.4 billion in revenues). Further, this performance was achieved in spite of the termination of a distribution agreement that was tied to the divested Respiratory Solutions unit and an unfavorable foreign currency translation impact of approximately 3.1 percent.
More specifically, looking at the volume growth that originated from specific units of BD, there were a number of areas that accounted for the overall gains the company saw in 2016.
The Medical segment experienced volume growth due to the Medication and Procedural Solutions unit’s sales of safety-engineered products, the Diabetes Care business’s sales of pen needles, and the Pharmaceutical Systems unit’s sales of self-injection systems. Life Sciences noted growth as a result of global sales of safety-engineered products from Preanalytical Systems, automated platform sales from Diagnostic Systems, and research instrument and reagent sales by the Biosciences unit. Infusion disposables and self-injection systems drove growth for the U.S. Medical segment. Internationally, safety-engineered and flush products drove growth for the Medical segment, while Life Sciences saw it from safety-engineered products, microbiology, women’s health platforms, and cancer platforms.
Examining the numbers for each segment of BD—Medical and Life Sciences—provides greater insight on where the company’s market strengths truly exist. The Medical segment, which accounted for $8.65 billion of the 2016 overall revenues, saw a 34 percent increase over 2015, a result of having the integrated CareFusion offerings as part of the company’s revenue streams for the full year (versus only half of the year in the 2015 fiscal year). Broken down further, by specific unit within the segment, the Medication and Procedural Solutions unit is the largest contributor to the company’s revenue, reporting $3.4 billion. The other units in the segment contributed revenue totals as follows: Medication Management Solutions—$2.2 billion; Diabetes Care—$1 billion; Pharmaceutical Systems—1.2 billion; and Respiratory Solutions—$824 million.
The Life Sciences segment contributed $3.8 billion to BD’s total revenues, a figure that was flat versus the prior year (up 0.2 percent). That segment is broken down into three, almost equal (in terms of revenue) units. Preanalytical Systems leads the segment with $1.4 billion, followed by Diagnostic Systems at $1.3 billion, and Biosciences posting $1.1 billion.
ANALYST INSIGHTS: Known for its solutions in cancer and diabetes, most were surprised when BD announced in May that it was acquiring CR Bard for $24 Billion. This acquisition will help BD leverage its global presence by accelerating end-to- end medication management and infection prevention, while creating new growth opportunities across a range of clinically impactful segments. It will also provide additional strength to BDs portfolio in the surgical arena. The key to success of this mega merger will very much be dependent on its execution of the post-merger integration.
—Dave Sheppard, Co-Founder and Principal, MedWorld Advisors
In terms of region, the company’s U.S. sales led revenue, representing $6.9 billion, compared to international sales that accounted for $5.6 billion. This was a reversal of 2015’s figures, which had international at $5.2 billion versus U.S. revenue of $5.1 billion. Again, the inclusion of CareFusion’s product lines had a direct impact on the increase in U.S. sales totals.
Enjoying increased sales revenues year over year from 2014 through 2016, the company mirrored those increases in its research and development spending. While a majority of the company’s R&D activity takes place within the United States, BD does conduct some internationally in China, France, India, Ireland, and Singapore. It also collaborates with universities and medical centers to further investigate potential new innovations. In total, BD spent $828 million on R&D in 2016. This represented a marked increase over 2015, during which $632 million was spent, and 2014, which saw R&D expenditures of $550 million.
Earlier investments in R&D are finally bearing fruit for the company as the 2016 fiscal year saw a fair number of notable product launches, FDA clearances/approvals, and CE mark notifications.
- Genesis Low-Temperature Sterilization Containers: These surgical instrument sterilization containers are validated for the latest low-temperature processes, including STERIS’ V-PRO System and Advanced Sterilization Products’ STERRAD Systems. The containers have a visually differentiated set of orange components that make it unique compared to other Genesis containers. They also provide an environmentally friendly alternative to sterilization wrap.
- FDA Clearance of New Syringe: This syringe was provided clearance for use with Humulin R U-500 insulin vials, required by diabetic patients requiring more than 200 units of insulin per day. The new syringe was developed to make it easier for users to draw the correct dose by reducing steps, avoiding potential errors.
- Antimicrobial Vascular Dressings: BD teamed with Vancive Medical Technologies to launch a new line of transparent vascular dressings that contain a CHG antimicrobial preservative. The BD ChloraShield dressings are secured to a patient’s skin via Vancive’s BeneHold CHG adhesive technology. The dressings are easily applied and removed, and with the microbial growth inhibitor, they are suitable for catheter insertion sites.
- Blood Collection and Separation Technology: BD received both a CE mark and FDA 510(k) clearance for its Vacutainer Barricor Tube. The system is a single-use, plastic evacuated tube used to collect, separate, transport, and process venous blood specimens to obtain high-quality plasma for in-vitro diagnostic use. The company claims the technology “improves sample quality, helps clinicians receive test results faster, and ultimately improves patient care and clinical efficiency.” It also states that the separator component reduces centrifugation time from 10 to three minutes.
- Blood Collection Set: The company received FDA 510(k) clearance and a CE mark for the Vacutainer UltraTouch Push Button Blood Collection Set. The design employs the company’s PentaPoint Comfort 5-bevel needle technology, which studies have demonstrated reduces the chance of a painful injection. The flatter, thinner surface helps penetrate the skin with greater ease.
- Automated Cervical Cancer Screening System: The BD Totalys MultiProcessor and BD Totalys SlidePrep instruments gained FDA approval during the 2016 fiscal year. These products, used in conjunction with BD’s FocalPoint SlideProfiler, compose the company’s Totalys System, “which further automates slide preparation, imaging, and review for use in cervical cancer screening, as well as providing ancillary testing aliquot capability.” The system is intended to be used by medium to high throughput cervical cancer screening labs, increasing workflow efficiency, reducing technician hands-on time and repetitive motion, and improving usability, user safety, quality, and functionality.
- Wireless Rapid Diagnostic System: The BD Veritor Plus System is used to detect influenza A and B, respiratory syncytial virus (RSV), and group A strep. The system also offers traceability and secure patient health record documentation features and functionality. The technology enables lab-quality immunoassay test results within minutes without the need for a laboratory. The device can be used in physician offices, clinics, hospitals, and integrated delivery networks. When used in conjunction with BD’s Cloud Connectivity Solution, test data can be wirelessly and securely transmitted to a patient’s EMR or laboratory information system.
The Veritor system wasn’t the only example of BD’s interest in connected technologies in 2016. The company also announced a collaboration agreement with Edwards Lifesciences in which the two firms would enable interoperability between patient hemodynamic management and IV fluid administration. Specifically, the agreement leverages Edwards’ advanced hemodynamic monitoring systems and fluid management algorithms and BD’s (CareFusion) Alaris Infusion Systems.
“This collaboration builds on our history of innovation in patient monitoring infusion solutions and the investments we’ve made in our interoperability platform that integrates the Alaris Infusion System to HIT systems. We are excited to extend that interoperability capability to integration with patient monitoring. Our vision is to create interoperability with many different types of systems and devices to help improve the patient care, efficiency, and cost of IV therapy,” J.C. Kyrillos, worldwide vice president and general manager of Infusion Solutions for BD, said in a statement announcing the agreement.
Further addressing medtech connectivity, BD announced another “partnership” of sorts in which the company stated that it was using AT&T Internet of Things (IoT) services to connect its wireless health devices. At the 2016 Healthcare Information and Management Systems Society annual meeting, the company presented the aforementioned Veritor System, which leverages the AT&T technology. BD is continuing to work with the communications giant on wireless connectivity solutions for other products.
“This collaboration with AT&T further strengthens BD’s continued progress in health IT and is a significant step forward for the company in becoming a leader in medical IoT technology,” said David Feygin, vice president, Health IT and Strategic Innovation at BD. “We are continuing to evaluate how the addition of information technology to our current capabilities could further benefit our customers and patients.”
